AzacitidineAntimetabolites, AntineoplasticMyelodysplastic SyndromesLeukemia, Myelomonocytic, ChronicSafetyChromatography, Supercritical FluidTreatment OutcomeCompassionate Use TrialsInjections, SubcutaneousLeukemia, Myeloid, AcuteAnemia, RefractoryConsolidation ChemotherapyInduction ChemotherapySafety ManagementAnemia, Refractory, with Excess of BlastsDrug ApprovalPatient SafetyDrug Administration ScheduleDNA MethylationDNA Modification MethylasesUnited States Food and Drug AdministrationSurvivalInternational AgenciesThalidomideEpigenomicsAntineoplastic Combined Chemotherapy ProtocolsRemission InductionBiological AvailabilityAntimetabolitesBlood TransfusionCytarabineRetrospective StudiesTetrazolium SaltsLeukemia, MyeloidRandomized Controlled Trials as TopicFood SafetyMaximum Tolerated DoseDouble-Blind MethodRecurrenceEquipment SafetyInfusions, IntravenousAcute DiseaseFatigueSurvival AnalysisConsumer Product SafetyHematopoietic Stem Cell TransplantationEnzyme InhibitorsDisease ProgressionCell Line, TumorDrug Therapy, CombinationTransplantation, HomologousDose-Response Relationship, Drug